CJC-1295 (No DAC) + IpamorelinAlso known as: CJC 1295 without DAC, CJC 1295 No DAC, Ipamorelin, Growth Hormone Releasing Hormone Analog (CJC-1295 No DAC), Growth Hormone Releasing Peptide (Ipamorelin)

Mechanism of Action

CJC-1295 without DAC is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) that stimulates the pituitary gland to release growth hormone (GH) in a pulsatile manner by mimicking endogenous GHRH activity. Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin receptor (GHSR-1a), which further stimulates GH secretion without significantly affecting cortisol or prolactin levels. Together, the combination synergistically enhances endogenous GH release through both GHRH receptor and ghrelin receptor pathways, resulting in increased physiological pulses of GH without desensitization.

Reported Research Benefits

Preclinical and laboratory research aimed at studying endogenous growth hormone secretion dynamics, muscle regeneration, fat metabolism, recovery from tissue injury, improved sleep quality, increased IGF-1 levels, and reduction of visceral fat in animal models. Valuable for endocrinology and regenerative medicine research.

Dosing Protocol & Reconstitution

Typically provided as lyophilized powder to be reconstituted with bacteriostatic water. Commonly used in subcutaneous injections in preclinical studies. Dosing varies according to experimental design; often repeated or chronic administration is employed to study long-term GH pulse effects. Researchers use peptide calculators to accurately prepare dosing concentrations.

Research Notes

The combination shows a balanced GH release profile with minimal side effects and reduced risk of prolactin elevation or cortisol increase compared to other GH secretagogues. It is favored for sustained GH pulse simulation in preclinical endocrinology models. Stability after reconstitution is up to 60 days refrigerated.

Research Summary

The combination of CJC-1295 (No DAC) and Ipamorelin is widely regarded as the gold-standard GH secretagogue stack. CJC-1295 provides the GHRH signal while Ipamorelin provides a synergistic GH pulse via ghrelin receptor activation, together producing robust GH secretion with minimal cortisol or prolactin elevation. This stack supports body recomposition, improved sleep quality, and recovery.

Side Effects & Safety

Generally well-tolerated. May cause mild water retention, fatigue, or headache especially early in use. Elevated GH/IGF-1 carries theoretical long-term risks. Ipamorelin's selectivity minimizes ACTH and cortisol side effects seen with older GHRPs.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: CJC-1295 (No DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+Ipamorelin+growth+hormone+secretagogue